MetaCap

Biodexa Pharmaceuticals American Depositary Shs (BDRX) vs Matinas Biopharma (MTNB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Biodexa Pharmaceuticals American Depositary Shs is the larger company by market cap ($982,950 vs $890,711), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BDRX+232.56%MTNB-71.12%
+670%+282%-106%
Oct 7, 20261 yearNov 20, 2026
BDRX+307.43%MTNB-72.13%
+681%+287%-108%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BDRX versus MTNB key metrics
MetricBDRXMTNB
Share price$1.88$0.7999
Market cap$982.95K$890.71K
1-day change-3.85%-1.26%
P/E ratio (TTM)0.00—
EPS (TTM)$509.89$-17.55
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-10.35M
52-week high$357.60$14.63
52-week low$1.85$0.75
Distance from 52-week high-99.48%-94.53%
Analyst consensusnone—
Avg. price target upside+375.20%—
Average volume618.91K80.86K
Shares outstanding524.24K1.11M
Employees112
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Biodexa Pharmaceuticals American Depositary Shs

BDRX stock →

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees

About Matinas Biopharma

MTNB stock →

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

BDRX vs MTNB FAQ

Which is bigger, Biodexa Pharmaceuticals American Depositary Shs or Matinas Biopharma?

Biodexa Pharmaceuticals American Depositary Shs (BDRX) is larger, with a market capitalization of $982.95K compared with $890.71K for Matinas Biopharma (MTNB).

Are Biodexa Pharmaceuticals American Depositary Shs and Matinas Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons